Table 5.
Association Between BRCA1 UTR Varients and Clinic pathological Features in Breast Cancer Cases
| Parameters | n | GG % | TT % | GT % | P-Value |
|---|---|---|---|---|---|
| Age Group | |||||
| Age<40 | 22 (22%) | 05 (22.72%) | 02 (9%) | 15 (68.18) | 0.554 |
| Age >40 | 78 (78%) | 21 (26.92%) | 06 (7.69%) | 51 (65.38%) | |
| Stage status | |||||
| Early stage | 37 (37%) | 11 (29.72%) | 6 (16.21%) | 20 (54%) | 0.03 |
| Advanced stage | 63 (63%) | 15 (23.80%) | 2 (3%) | 46 (73%) | |
| Grade status | |||||
| Grade I | 14 (14%) | 07 (50%) | 01 (10%) | 06 (40%) | 0.07 |
| Grade II | 33 (33%) | 06 (18.25%) | 2 (6%) | 25 (75.75%) | |
| Grade III | 53 (53%) | 13 (24.52%) | 5 (9.43%) | 35 (66%) | |
| Distant metastasis | |||||
| Positive | 65 (65%) | 10 (15.38%) | 05 (7.79%) | 50 (76.92%) | 0.003 |
| Negative | 35 (35%) | 16 (45.71%) | 03 (8.57%) | 16 (45.71%) | |
| Estrogen receptor status | |||||
| Positive | 67 (67%) | 20 (29.85%) | 05 (7.46%) | 42 (62.68%) | 0.45 |
| Negative | 33 (33%) | 06 (18.18%) | 03 (9%) | 24 (72.72%) | |
| Progesterone Receptor status | |||||
| Positive | 64 (64%) | 13 (20.31%) | 05 (7.81%) | 46 (71.87%) | 0.72 |
| Negative | 36 (36%) | 13 (36.11%) | 3 (8.33%) | 20 (55.55%) | |
| Her2/neu status | |||||
| Positive | 60 (60%) | 15 (25%) | 05 (8.33%) | 40 (66.66%) | 0.44 |
| Negative | 40 (40%) | 11 (27.5%) | 03 (7.5%) | 26 (65%) |